The content on this site is intended for healthcare professionals only
Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma
ZUMA-12: A phase 2 study of axi-cel as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL)
Potentially targetable pathways ID’d for augmenting CAR-T cell therapy for DLBCL
Mosunetuzumab induces deep and durable remissions in 3L R/R follicular lymphoma
Study indicates circulating tumour cell assessment should be part of multiple myeloma diagnostic workup
Initial treatment options for relapsed/refractory multiple myeloma patients
ZUMA-5 update: Axicabtagene ciloleucel continues to show strong effect in R/R iNHL
Lisocabtagene maraleucel demonstrates improvement over standard of care in 2L LBCL
Latest in advanced endometrial cancer
Oncology nursing in the global south during COVID-19
OncoAlert and ecancer weekly round up for November 29th - December 5th, 2021
Post-HSCT management of ALL - Adult ALL perspective
